SLNO

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Soleno Therapeutics Inc

NASDAQ | SLNO

64.92

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 14, 2025)

$3.42B

Market Cap

-

P/E Ratio

-4.22

EPS

$90.32

52 Week High

$41.50

52 Week Low

HEALTHCARE

Sector

SLNO Chart

Recent Chart
Price Action

SLNO Technicals

Tags:

SLNO Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$184M
Selling General And Administrative $106M
Research And Development $79M
Operating Expenses $188M
Investment Income Net -
Net Interest Income $12M
Interest Income $12M
Interest Expense $231K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax -$176M
Income Tax Expense -$176M
Interest And Debt Expense -
Net Income From Continuing Operations -$176M
Comprehensive Income Net Of Tax -
Ebit -$184M
Ebitda -$174M
Net Income -$176M

Revenue & Profitability

Earnings Performance

SLNO Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $331M
Total Current Assets $294M
Cash And Cash Equivalents At Carrying Value $88M
Cash And Short Term Investments $88M
Inventory -
Current Net Receivables -
Total Non Current Assets $37M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $6.8M
Intangible Assets Excluding Goodwill $6.8M
Goodwill -
Investments -
Long Term Investments $27M
Short Term Investments $204M
Other Current Assets $2.5M
Other Non Current Assets -
Total Liabilities $86M
Total Current Liabilities $19M
Current Accounts Payable $8.9M
Deferred Revenue -
Current Debt -
Short Term Debt $526K
Total Non Current Liabilities $67M
Capital Lease Obligations $3M
Long Term Debt $50M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $53M
Other Current Liabilities $9.3M
Other Non Current Liabilities $15M
Total Shareholder Equity $245M
Treasury Stock -
Retained Earnings -$452M
Common Stock $46K
Common Stock Shares Outstanding $40M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$69M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $2M
Capital Expenditures $218K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$226M
Cashflow From Financing $213M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$176M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$184M
Selling General And Administrative $106M
Research And Development $79M
Operating Expenses $188M
Investment Income Net -
Net Interest Income $12M
Interest Income $12M
Interest Expense $231K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax -$176M
Income Tax Expense -$176M
Interest And Debt Expense -
Net Income From Continuing Operations -$176M
Comprehensive Income Net Of Tax -
Ebit -$184M
Ebitda -$174M
Net Income -$176M

SLNO News

SLNO Profile

Soleno Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, dedicated to developing innovative therapies for rare diseases. With a strong emphasis on addressing unmet medical needs, Soleno leverages its proprietary drug development platform to advance treatments through clinical trials. The company's commitment to therapeutic innovation positions it as a key player in the rare disease space, making it an intriguing investment opportunity for institutional investors seeking exposure to cutting-edge biopharmaceutical advancements.

VHAI
+66.66%
$0.00
YYAI
-9.70%
$0.15
CGBS
-39.47%
$0.03
BURU
-23.61%
$0.39
BITF
+8.44%
$5.84
NVDA
-2.55%
$183.50
TMQ
+47.54%
$9.67
PLUG
-0.25%
$3.89
NVTS
+30.49%
$13.00
CAN
+17.03%
$1.77
SSKN
+44.75%
$2.22
RGTI
+1.74%
$55.87
LAES
+19.88%
$7.34
DNN
+6.33%
$3.27
ITP
+24.30%
$0.32
BYND
-22.70%
$0.80
EDHL
+91.46%
$0.95
INTC
-2.12%
$36.42
AXDX
-61.36%
$0.03
CRML
+28.39%
$29.88
MNTS
+23.42%
$1.76
NAK
+2.81%
$2.73
IONZ
+6.95%
$2.46
SOUN
+10.25%
$19.14
DFLI
+44.03%
$1.57
F
+1.42%
$11.70
DVLT
-10.52%
$1.70
TLRY
-2.96%
$1.63
ONDS
+17.24%
$10.81
RR
+8.95%
$6.45
AMD
+2.99%
$222.90
WULF
+12.67%
$15.77
GPUS
-7.04%
$0.39
ETHD
+5.70%
$3.52
NUAI
+42.55%
$3.35
ERIC
+20.26%
$9.82
ACHR
+0.64%
$12.85
KDLY
-1.56%
$0.85
MARA
+9.33%
$22.12
UUUU
+11.50%
$26.50
RXRX
-0.99%
$5.47
CIFR
+3.93%
$21.14
QBTS
+5.48%
$42.84
UAMY
+9.24%
$18.25
JDZG
+37.23%
$2.58
AREC
+30.92%
$6.51
BBD
+2.58%
$3.17
RMBL
+60.50%
$3.21
TSLA
-1.38%
$429.85
ADD
-25.47%
$0.05
BTBT
+7.12%
$4.28
RIG
-1.87%
$3.14
CLSK
+9.75%
$21.99
USAR
+2.43%
$39.62
SRM
+53.27%
$10.30
PLTR
+2.50%
$181.65
ADAP
-11.93%
$0.15
SOFI
+2.18%
$27.73
NIO
-3.06%
$6.95
ABAT
+18.65%
$10.94
JOBY
+5.63%
$17.71
NOK
+4.57%
$5.49
IREN
+6.40%
$68.25
CLF
+0.72%
$13.93
WWR
+14.25%
$2.92
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
APLD
+9.34%
$37.44
AAL
+2.51%
$12.03
WLGS
-5.57%
$0.04
QS
-2.14%
$16.62
GGB
+2.85%
$3.24
MP
+2.98%
$97.90
ETWO
0.00%
$3.30
GWH
-19.99%
$7.24
ASST
-4.16%
$1.03
BMNR
-5.11%
$53.94
ASPI
+31.49%
$13.32
BTG
+0.74%
$5.34
AMC
-2.71%
$2.87
JBLU
+9.12%
$4.96
RGTZ
-3.00%
$9.02
EOSE
+2.55%
$17.48
SNAP
-0.93%
$7.97
PFE
-0.14%
$24.69
QUBT
-0.04%
$21.45
AMZN
-0.61%
$218.72
AFMD
-34.94%
$0.18
NAKA
-6.15%
$0.80
GWAV
+84.53%
$15.70
GDXD
+0.44%
$0.73
NB
+4.41%
$11.81
BCRX
-10.95%
$6.26
RF
+1.91%
$25.03
ABEV
+1.36%
$2.16
REKR
+22.35%
$2.54
SLDP
+7.50%
$6.30
OPI
-16.97%
$0.20
ATXS
+38.78%
$11.75
WFC
+7.55%
$84.88
VHAI
+66.66%
$0.00
YYAI
-9.70%
$0.15
CGBS
-39.47%
$0.03
BURU
-23.61%
$0.39
BITF
+8.44%
$5.84
NVDA
-2.55%
$183.50
TMQ
+47.54%
$9.67
PLUG
-0.25%
$3.89
NVTS
+30.49%
$13.00
CAN
+17.03%
$1.77
SSKN
+44.75%
$2.22
RGTI
+1.74%
$55.87
LAES
+19.88%
$7.34
DNN
+6.33%
$3.27
ITP
+24.30%
$0.32
BYND
-22.70%
$0.80
EDHL
+91.46%
$0.95
INTC
-2.12%
$36.42
AXDX
-61.36%
$0.03
CRML
+28.39%
$29.88
MNTS
+23.42%
$1.76
NAK
+2.81%
$2.73
IONZ
+6.95%
$2.46
SOUN
+10.25%
$19.14
DFLI
+44.03%
$1.57
F
+1.42%
$11.70
DVLT
-10.52%
$1.70
TLRY
-2.96%
$1.63
ONDS
+17.24%
$10.81
RR
+8.95%
$6.45
AMD
+2.99%
$222.90
WULF
+12.67%
$15.77
GPUS
-7.04%
$0.39
ETHD
+5.70%
$3.52
NUAI
+42.55%
$3.35
ERIC
+20.26%
$9.82
ACHR
+0.64%
$12.85
KDLY
-1.56%
$0.85
MARA
+9.33%
$22.12
UUUU
+11.50%
$26.50
RXRX
-0.99%
$5.47
CIFR
+3.93%
$21.14
QBTS
+5.48%
$42.84
UAMY
+9.24%
$18.25
JDZG
+37.23%
$2.58
AREC
+30.92%
$6.51
BBD
+2.58%
$3.17
RMBL
+60.50%
$3.21
TSLA
-1.38%
$429.85
ADD
-25.47%
$0.05
BTBT
+7.12%
$4.28
RIG
-1.87%
$3.14
CLSK
+9.75%
$21.99
USAR
+2.43%
$39.62
SRM
+53.27%
$10.30
PLTR
+2.50%
$181.65
ADAP
-11.93%
$0.15
SOFI
+2.18%
$27.73
NIO
-3.06%
$6.95
ABAT
+18.65%
$10.94
JOBY
+5.63%
$17.71
NOK
+4.57%
$5.49
IREN
+6.40%
$68.25
CLF
+0.72%
$13.93
WWR
+14.25%
$2.92
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
APLD
+9.34%
$37.44
AAL
+2.51%
$12.03
WLGS
-5.57%
$0.04
QS
-2.14%
$16.62
GGB
+2.85%
$3.24
MP
+2.98%
$97.90
ETWO
0.00%
$3.30
GWH
-19.99%
$7.24
ASST
-4.16%
$1.03
BMNR
-5.11%
$53.94
ASPI
+31.49%
$13.32
BTG
+0.74%
$5.34
AMC
-2.71%
$2.87
JBLU
+9.12%
$4.96
RGTZ
-3.00%
$9.02
EOSE
+2.55%
$17.48
SNAP
-0.93%
$7.97
PFE
-0.14%
$24.69
QUBT
-0.04%
$21.45
AMZN
-0.61%
$218.72
AFMD
-34.94%
$0.18
NAKA
-6.15%
$0.80
GWAV
+84.53%
$15.70
GDXD
+0.44%
$0.73
NB
+4.41%
$11.81
BCRX
-10.95%
$6.26
RF
+1.91%
$25.03
ABEV
+1.36%
$2.16
REKR
+22.35%
$2.54
SLDP
+7.50%
$6.30
OPI
-16.97%
$0.20
ATXS
+38.78%
$11.75
WFC
+7.55%
$84.88
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.